The codelivery of massive TAAs and novel adjuvant OMVs to LNs provoke effective antigen presentation and DCs maturation, and then intense CD8+ T-based immunotherapeutic efficacy in the xenografted, metastatic as well as recurrent tumor models of mice, providing a potential strategy for putting forward the cancer immunotherapy. This evidence concerns the gene CD8A and neoplasm.